An investigation on behalf of investors of Zymeworks Inc (NYSE:ZYME) shares over potential securities laws violations by Zymeworks Inc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Zymeworks Inc (NYSE:ZYME) concerning whether a series of statements by Zymeworks Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. Zymeworks Inc reported that its annual Total Revenue rose from $9.66 million in 2015 to $11.01 million in 2016. On April 28, 2017, Zymeworks Inc sold 4.5 million shares of stock in its initial public stock offering (the 'IPO'), raising $58.50 million in new capital. However, since the IPO, Zymeworks Inc stock declined to as low as $7.26 per share.